Agios Pharmaceuticals Inc. diskutieren
Agios Pharmaceuticals Inc.
WKN: A1W2RM / Symbol: AGIO / Name: Agios / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
21,00 €
-2,80 %
Sell Agios Pharmaceuticals Inc.
Sell Agios Pharmaceuticals Inc.
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target lowered by analysts at Royal Bank of Canada from $43.00 to $42.00. They now have an "outperform" rating on the stock.
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target raised by analysts at Royal Bank of Canada from $44.00 to $53.00. They now have an "outperform" rating on the stock.
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target raised by analysts at Royal Bank of Canada from $53.00 to $55.00. They now have an "outperform" rating on the stock.
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $55.00 price target on the stock.
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $51.00 price target on the stock.
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $55.00 price target on the stock.
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target raised by analysts at Royal Bank of Canada from $55.00 to $57.00. They now have an "outperform" rating on the stock.
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $58.00 price target on the stock.
Ratings data for AGIO provided by MarketBeat
Neueste Beiträge
Jefferies_Financial_ in M&T Bank Corp. diskutieren